{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:03:17Z","timestamp":1776405797990,"version":"3.51.2"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.esmoop.2022.100405","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T19:41:36Z","timestamp":1647459696000},"page":"100405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes"],"prefix":"10.1016","volume":"7","author":[{"given":"Y.","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7153","key":"10.1016\/j.esmoop.2022.100405_bib1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.esmoop.2022.100405_bib2","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/0008-5472.CAN-11-3990","article-title":"The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation","volume":"72","author":"Jun","year":"2012","journal-title":"Cancer Res"},{"issue":"35","key":"10.1016\/j.esmoop.2022.100405_bib3","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100405_bib4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100405_bib5","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s12253-019-00685-2","article-title":"Methods for identifying patients with tropomyosin receptor kinase (TRK) fusion cancer","volume":"26","author":"Wong","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.esmoop.2022.100405_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202000016","article-title":"Sequencing strategies for fusion gene detection","volume":"42","author":"Heyer","year":"2020","journal-title":"Bioessays"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100405_bib7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1101\/gr.186114.114","article-title":"INTEGRATE: gene fusion discovery using whole genome and transcriptome data","volume":"26","author":"Zhang","year":"2016","journal-title":"Genome Res"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100405_bib8","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/j.jtho.2019.04.012","article-title":"A\u00a0novel intergenic region between CENPA and DPYSL5-ALK exon 20 fusion variant responding to crizotinib treatment in a patient with lung adenocarcinoma","volume":"14","author":"Fei","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2022.100405_bib9","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jtho.2020.02.023","article-title":"Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC","volume":"15","author":"Li","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2022.100405_bib10","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1016\/j.cllc.2020.04.014","article-title":"Chr2 30297612-ALK, a novel intergenic fusion with exon18 of ALK, responds to crizotinib","volume":"21","author":"Chen","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100405_bib11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40291-019-00389-y","article-title":"Clinicopathological features of ALK expression in 9889 cases of non-small-cell lung cancer and genomic rearrangements identified by capture-based next-generation sequencing: a Chinese retrospective analysis","volume":"23","author":"Zhao","year":"2019","journal-title":"Mol Diagn Ther"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100405_bib12","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00432-019-03116-6","article-title":"Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes","volume":"146","author":"Tian","year":"2020","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100405_bib13","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jtho.2020.02.007","article-title":"Detection of nonreciprocal\/reciprocal ALK translocation as poor predictive marker in patients with first-line crizotinib-treated ALK-rearranged NSCLC","volume":"15","author":"Zhang","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100405_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014826","article-title":"ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: a case report","volume":"98","author":"Qiu","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100405_bib15","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2020.03.009","article-title":"A\u00a0novel linc00308\/D21S2088E intergenic region ALK fusion and its enduring clinical responses to crizotinib","volume":"15","author":"Zhang","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100405_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cllc.2019.09.004","article-title":"Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR+ NSCLC: results from a large-scale survey of NTRK1 fusions in Chinese patients with lung cancer","volume":"21","author":"Xia","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100405_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lungcan.2017.02.005","article-title":"Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. pitfall of solely relying on liquid re-biopsy?","volume":"106","author":"Ou","year":"2017","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100405_bib18","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jtho.2018.05.041","article-title":"Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples","volume":"13","author":"Davies","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100405_bib19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41598-017-00520-1","article-title":"Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types","volume":"7","author":"Shu","year":"2017","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.esmoop.2022.100405_bib20","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.esmoop.2022.100405_bib21","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"issue":"23","key":"10.1016\/j.esmoop.2022.100405_bib22","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1093\/bioinformatics\/btu549","article-title":"FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution","volume":"30","author":"Newman","year":"2014","journal-title":"Bioinformatics"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100405_bib23","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100405_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2012","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100405_bib25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/bib\/bbs017","article-title":"Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration","volume":"14","author":"Thorvaldsdottir","year":"2013","journal-title":"Brief Bioinform"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100405_bib26","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-09-2845","article-title":"A\u00a0novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry","volume":"16","author":"Mino-Kenudson","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"7510","key":"10.1016\/j.esmoop.2022.100405_bib27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature13379","article-title":"Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma","volume":"511","author":"Northcott","year":"2014","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.esmoop.2022.100405_bib28","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/hmg\/ddm145","article-title":"Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene","volume":"16","author":"Demura","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100405_bib29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/cam4.1324","article-title":"Epigenetic silencing of RNF144A expression in breast cancer cells through promoter hypermethylation and MBD4","volume":"7","author":"Zhang","year":"2018","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100405_bib30","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1096\/fj.201902259R","article-title":"KRCC1: A potential therapeutic target in ovarian cancer","volume":"34","author":"Dwivedi","year":"2020","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100405_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/onc.2011.218","article-title":"Identification of MAGI1 as a tumor-suppressor protein induced by cyclooxygenase-2 inhibitors in colorectal cancer cells","volume":"31","author":"Zaric","year":"2012","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100405_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.21147\/j.issn.1000-9604.2017.01.04","article-title":"MAGI1 inhibits migration and invasion via blocking MAPK\/ERK signaling pathway in gastric cancer","volume":"29","author":"Jia","year":"2017","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100405_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/cancers12010223","article-title":"MAGI1, a new potential tumor suppressor gene in estrogen receptor positive breast cancer","volume":"12","author":"Alday-Parejo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2022.100405_bib34","first-page":"100112","article-title":"A\u00a0novel LINC00478\/LINC01549 intergenic region-ALK fusion responded well to alectinib in a patient with lung adenocarcinoma","volume":"2","author":"Peng","year":"2020","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100405_bib35","first-page":"100106","article-title":"A\u00a0case of lung adenocarcinoma harboring a rare LOC285000-ALK-NCK2 gene fusion identified by next-generation sequencing with long-term response to crizotinib","volume":"2","author":"Zhang","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.esmoop.2022.100405_bib36","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s00432-021-03526-5","article-title":"An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma","volume":"147","author":"Dou","year":"2021","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100405_bib37","doi-asserted-by":"crossref","first-page":"670907","DOI":"10.3389\/fonc.2021.670907","article-title":"Novel MRPS9-ALK fusion mutation in a lung adenocarcinoma patient: a case report. case report","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2022.100405_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2020.12.013","article-title":"Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib","volume":"152","author":"Zhao","year":"2021","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100405_bib39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/cjp2.208","article-title":"Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population","volume":"7","author":"Zhao","year":"2021","journal-title":"J\u00a0Pathol Clin Res"},{"key":"10.1016\/j.esmoop.2022.100405_bib40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.lungcan.2020.12.018","article-title":"Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients","volume":"152","author":"Cai","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100405_bib41","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.lungcan.2021.02.008","article-title":"Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib","volume":"154","author":"Wang","year":"2021","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100405_bib42","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jtho.2020.12.016","article-title":"A\u00a0novel intergenic region between KLHL31 and LRRC1-ALK exon 20 fusion variant in advanced lung adenocarcinoma and its remarkable response to ALK Inhibitor","volume":"16","author":"Qiu","year":"2021","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:04Z","timestamp":1761856024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2059702922000266"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100405","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100405"}}